Aida adds three drugs to pipeline

By Elaine Rigoli

Tampa, Fla., June 13 - Aida Pharmaceuticals, Inc. has expanded its drug-development pipeline to seven developmental drugs from four drugs.

The three new drugs are either being evaluated for preclinical trials or in various early stages of applied research and include prodigiosin to treat pancreatic cancer, anti-CD86 monoclonal antibody to treat immunity diseases and anti-CTLA-4 monoclonal antibody to inhibit tumor growth.

"Each of these drugs represent a unique scientific opportunity to improve health care for critical patients. Physicians and patients are demanding non-invasive biochemical therapies; Aida Pharmaceuticals has the knowledge and capacity to develop and deliver these therapies over the long-term," chairman Jin Biao said in a news release.

"I believe the ongoing development and subsequent commercialization of our product pipeline will drive future sales and enhance shareholder value."

Hangzhou, China-based Aida Pharmaceuticals is a product-focused company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of pharmaceutical and genetic products in mainland China.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.